Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
27.15
52.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Dizal Jiangsu Pharmaceutical Co Ltd
Common Stock
Dizal Jiangsu Pharmaceutical Co Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
D
|
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
|
Common Stock
ÂĄ408.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Common Stock
ÂĄ906k
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Common Stock
ÂĄ59k
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Common Stock
ÂĄ1.3B
|
CAGR 3-Years
43%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Common Stock
ÂĄ6.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
27%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Common Stock
ÂĄ2.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
Dizal Jiangsu Pharmaceutical Co Ltd
Glance View
Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.
See Also
What is Dizal Jiangsu Pharmaceutical Co Ltd's Common Stock?
Common Stock
408.2m
CNY
Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Common Stock amounts to 408.2m CNY.
What is Dizal Jiangsu Pharmaceutical Co Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
-11%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 4% over the past three years , -11% over the past five years .